

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



绿竹生物
LUZHU BIOTECH

Beijing Luzhu Biotechnology Co., Ltd.

北京綠竹生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2480)

VOLUNTARY ANNOUNCEMENT RECOMBINANT RSV VACCINE OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

This announcement is made by Beijing Luzhu Biotechnology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the recombinant respiratory syncytial virus (“**RSV**”) vaccine (the “**Recombinant RSV Vaccine**”) developed by the Group has been approved by the National Medical Products Administration of the People's Republic of China (the “**PRC**” or “**China**”) for clinical trials in the PRC.

The product is a recombinant protein vaccine candidate independently developed by the Group for the prevention of lower respiratory tract disease (LRTD) caused by RSV. It is a liquid formulation vaccine containing aluminum adjuvant and uses RSV pre-fusion F (Pre-F) protein antigen. The approval of this clinical trial has laid a solid foundation for the Group's subsequent development of recombinant protein vaccine candidates.

ABOUT THE RECOMBINANT RSV VACCINE

RSV is a common respiratory pathogen, and infection in susceptible populations may develop into severe conditions such as bronchiolitis and pneumonia. At present, there is no RSV-specific therapeutic drug in China, and clinical treatment is mainly symptomatic and supportive. There is an urgent clinical need for RSV vaccines. The Recombinant RSV Vaccine can induce the body to produce humoral immunity and cellular immunity, and is a potential candidate vaccine for the prevention of lower respiratory tract infections caused by RSV and the protection of susceptible populations.

ABOUT THE COMPANY

The Company is a biotechnology company committed to developing innovative human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Since its inception in 2001, the Group has focused on human medicine and has established technology platforms with its understanding of immunology and protein engineering, which empowers the Group to develop the recombinant vaccine and antibody product candidates with favorable efficiency, high purity and improved stability.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that the Recombinant RSV Vaccine will ultimately be successfully developed and marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Beijing Luzhu Biotechnology Co., Ltd.
Chairman and Executive Director
Mr. KONG Jian

Hong Kong, October 12, 2026

As of the date of this announcement, the Board comprises Mr. KONG Jian, Ms. PENG Ling and Ms. ZHANG Yanping as executive Directors; Mr. MA Biao and Mr. KONG Shuangquan as non-executive Directors; and Ms. HOU Aijun, Mr. LEUNG Wai Yip and Mr. LIANG Yeshe as independent non-executive Directors.